BiomX Inc. (NYSEMKT:PHGE – Get Rating) – Research analysts at HC Wainwright raised their Q2 2023 earnings per share estimates for BiomX in a report released on Monday, May 15th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.12) per share for the quarter, up from their prior forecast of ($0.21). The consensus estimate for BiomX’s current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for BiomX’s Q3 2023 earnings at ($0.12) EPS, Q4 2023 earnings at ($0.14) EPS, FY2023 earnings at ($0.55) EPS, FY2024 earnings at ($0.47) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.45) EPS and FY2027 earnings at ($0.36) EPS.
BiomX Price Performance
PHGE opened at $0.28 on Thursday. The firm has a market cap of $9.19 million, a PE ratio of -0.31 and a beta of 1.32. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.23 and a quick ratio of 4.65. The business’s 50 day moving average is $0.29 and its two-hundred day moving average is $0.29.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in BiomX by 76.6% during the 2nd quarter. Renaissance Technologies LLC now owns 42,200 shares of the company’s stock worth $31,000 after acquiring an additional 18,300 shares during the period. Jane Street Group LLC acquired a new stake in BiomX during the 1st quarter worth approximately $48,000. Millennium Management LLC lifted its position in BiomX by 208.6% during the 4th quarter. Millennium Management LLC now owns 270,848 shares of the company’s stock worth $51,000 after acquiring an additional 183,091 shares during the period. Finally, Susquehanna International Group LLP lifted its position in BiomX by 372.4% during the 1st quarter. Susquehanna International Group LLP now owns 195,598 shares of the company’s stock worth $60,000 after acquiring an additional 154,189 shares during the period. Hedge funds and other institutional investors own 30.55% of the company’s stock.
In other BiomX news, major shareholder Israel Biofund Gp Limi Orbimed acquired 348,000 shares of the company’s stock in a transaction dated Monday, February 27th. The shares were acquired at an average price of $0.24 per share, for a total transaction of $83,520.00. Following the acquisition, the insider now owns 3,161,489 shares in the company, valued at approximately $758,757.36. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 5.30% of the company’s stock.
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
- Get a free copy of the StockNews.com research report on BiomX (PHGE)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.